Oncopeptides carries out a 300 million SEK rights issue
Find more information including questions and answers here.
Link to rights issue page, Oncopeptalks, Q&A for investors and recorded webcast
Find more information including questions and answers here.
Link to rights issue page, Oncopeptalks, Q&A for investors and recorded webcast
March 22, 2024 – Sofia Heigis, CEO, presents Oncopeptides to BioStock, Scandinavia’s leading digital news and analysis service with an exclusive focus on companies in the Life Science sector.
Oncopeptides’ CEO Sofia Heigis presented at Redeye’s event: Commercialization in Life Science on March 20, 2024.
March 27, 2024
Oncopeptides AB and Vector Pharma FZCO (“Vector”) today announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle East and North Africa (“MENA”).
Read moreFebruary 23, 2024
Oncopeptides AB (publ) today announces that the U.S. Food and Drug Administration (FDA) has made a decision regarding the withdrawal of Pepaxto, which Oncopeptides had appealed.
Read moreFebruary 23, 2024
Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the Spanish Drug Pricing Authority (CIPM) has published a positive recommendation for the pricing of melflufen, branded in Europe as Pepaxti.
Read moreMarch 1, 2024
Oncopeptides today announces that a new article analyzing scientific data on melflufen, marketed in Europe as Pepaxti, was recently published in the peer-reviewed medical journal Clinical Lymphoma, Myeloma and Leukemia.
Read moreFebruary 29, 2024
Oncopeptides today announces that a new article analyzing health-related quality of life in patients treated with melflufen, marketed in Europe as Pepaxti, has been published in Haematologica.
Read moreFebruary 7, 2024
Oncopeptides recently received a favorable opinion from EMA to revert back to the originally approved indication for Pepaxti. This means that the previously communicated decision to opt out of the process to extend the indication has now been fully realized.
Read moreMarch 22, 2024
Sofia Heigis, CEO, presents Oncopeptides to BioStock, Scandinavia’s leading digital news and analysis service with an exclusive focus on companies in the Life Science sector.
Read moreMarch 19, 2024
On Monday, Oncopeptides' CEO Sofia Heigis was interviewed by Redeye's life science analyst Richard Ramanius. The conversation touched on, among other things, the recently announced new rights issue, what the European market for multiple myeloma drugs looks like and status on the ongoing commercialization in Europe.
Read moreMarch 18, 2024
Oncopeptides’ CEO Sofia Heigis will present at Redeye’s event: Commercialization in Life Science on March 20, 2024.
Read morePress release - March 27, 2024
Released February 27, 2024
CEO Sofia Heigis
David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68
Oncopeptides AB Q1 interim report 2024 will be published May 30, 2024
2024-04-15
Meeting
2024-04-22
Report
2024-04-29 - 2024-05-29
Other
”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”
We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.